334 related articles for article (PubMed ID: 28921038)
1. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
Wang L; Zhang S; Xi J; Li W; Zhou L; Lu J; Lu J; Zhang T; Zhao C
J Neurol; 2017 Nov; 264(11):2191-2200. PubMed ID: 28921038
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH; Shin HY; Kim SM
Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic efficacy and safety of tacrolimus for intractable myasthenia gravis: a report of 36 patients].
Feng HY; Liu WB; Qiu L; Huang X; Huang RX
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(45):3190-2. PubMed ID: 22333101
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
Zhao LN; Liang Y; Fang XJ; Liu XM; Jiang QL; Wang SS; She SF; Cao M
Clin Neurol Neurosurg; 2018 Oct; 173():70-76. PubMed ID: 30092406
[TBL] [Abstract][Full Text] [Related]
7. [A child with generalized myasthenia gravis successfully treated with tacrolimus].
Goto T; Mori M; Yamagata T; Mizuguchi M; Momoi MY
No To Hattatsu; 2007 Jul; 39(4):300-3. PubMed ID: 17633089
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis.
Tao X; Wang W; Jing F; Wang Z; Chen Y; Wei D; Huang X
Neurol Sci; 2017 Feb; 38(2):325-330. PubMed ID: 27873026
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).
Konishi T; Yoshiyama Y; Takamori M; Saida T
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):448-50. PubMed ID: 15716549
[TBL] [Abstract][Full Text] [Related]
11. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis.
Yoshikawa H; Kiuchi T; Saida T; Takamori M
J Neurol Neurosurg Psychiatry; 2011 Sep; 82(9):970-7. PubMed ID: 21784757
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis.
Itani K; Nakamura M; Wate R; Kaneko S; Fujita K; Iida S; Morise S; Murakami A; Kunieda T; Takenouchi N; Yakushiji Y; Kusaka H
Neuromuscul Disord; 2021 Jun; 31(6):512-518. PubMed ID: 33903022
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic and Immunoregulatory Effects of Tacrolimus in Patients with Refractory Generalized Myasthenia Gravis.
Wu H; Wang Z; Xi J; Liu J; Yan C; Song J; Wang L; Jing S; Wang Y; Zhao C
Eur Neurol; 2020; 83(5):500-507. PubMed ID: 32932253
[TBL] [Abstract][Full Text] [Related]
14. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus.
Nagaishi A; Yukitake M; Kuroda Y
Intern Med; 2008; 47(8):731-6. PubMed ID: 18421189
[TBL] [Abstract][Full Text] [Related]
16. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
Wu H; Chen L; Zhou X; Wu Y; Yan Y; Zhu Y; Zhao C; Xue Q
J Neuroimmunol; 2022 Nov; 372():577955. PubMed ID: 36054935
[TBL] [Abstract][Full Text] [Related]
17. Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis.
Fan Z; Lei L; Su S; Zhang S; Xie N; Li L; Lu Y; Di L; Wang M; Xu M; Shen XM; Da Y
Ann Clin Transl Neurol; 2023 Apr; 10(4):589-598. PubMed ID: 36808840
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of a 2-year-old girl with intractable myasthenia gravis using tacrolimus.
Kakisaka Y; Haginoya K; Yokoyama H; Ishitobi M; Wakusawa K; Sato I; Togashi N; Kitamura T; Fukuyo N; Yoshihara Y; Iinuma K
Brain Dev; 2006 Sep; 28(8):534-6. PubMed ID: 16564661
[TBL] [Abstract][Full Text] [Related]
19. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis.
Kawaguchi N; Yoshiyama Y; Nemoto Y; Munakata S; Fukutake T; Hattori T
Curr Med Res Opin; 2004 Aug; 20(8):1269-73. PubMed ID: 15324529
[TBL] [Abstract][Full Text] [Related]
20. A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis.
Ahn SW; Joo IS; Kim BJ; Sung JJ; Kang SY; Oh J; Minn YK; Suh BC; Oh SY; Hong YH; Nam TS; Seok JI; Park YE; Shin HY; Cho EB; Shin JY; Seok HY; Park JS; Min JH; Seok JM; Kim BJ
J Neurol Sci; 2017 Aug; 379():271-275. PubMed ID: 28716258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
